PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
(FDG)-positron emission tomography revealed positive FDG uptake in the pulmonary artery mass (e) and in the chest wall tumor (f).
Ohtsuka et al., "[F-18] Fluorodeoxyglucose
positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas," Japanese Journal of Clinical Oncology, vol.
A PET/CT showed a high accumulation of fluorodeoxyglucose
(FDG) to the left neck mass, and there was a slight laterality of FDG accumulation in the tonsils with the right-side predominance.
Bodenner, "Incidence of thyroid carcinoma in fluorodeoxyglucose
positron emission tomography-positive thyroid incidentalomas," Otolaryngology - Head and Neck Surgery, vol.
Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose
whole-body PET: correlation with histopathologic and CT findings.
uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role.
, "currently the 'workhorse' in clinical PET imaging, has a good sensitivity but limited specificity, as several types of benign breast tumors and conditions can be [sup.18]FDG-avid and mimic malignancy," Dr.
In relevant remarks in April, Head of the AEOI Ali Akbar Salehi announced Iran has set up a unit to produce oxygen-18 isotope which is an important precursor for the production of fluorodeoxyglucose
used in positron emission tomography.
(FDG) PET scan reveals how active the different parts of the brain are based on how much sugar (glucose) those areas use for their fuel.
(FDG) is a glucose analog used as a tracer to detect the hypermetabolic activity of tumors.
In the study, Duke Medicine researchers examined the accuracy of three tests--magnetic resonance imaging (MRI), fluorodeoxyglucose
positron emission tomography (FDG-PET)--and cerebrospinal fluid analysis, to determine which combination of tests proved most effective at predicting the development of AD in an individual with mild cognitive impairment (MCI).